Navitas Life Sciences

Navitas Life Sciences delivers platform-driven full-service Clinical, Regulatory, and Safety solutions and services. Navitas operates across North America, Europe, Asia Pacific, and Latin America. Navitas brings together the capabilities of a full-service CRO, a technology-led life sciences services provider, and expertise in analytics and data sciences to address critical challenges and drive outcomes for life sciences.

Navitas has over 30 years of rich experience across 550+ phase I-IV clinical trials, 1400 bioequivalence studies, 20+ therapeutic areas, and 40+ successful GCP/non-GCP audits. Our trial expertise is augmented by OneClinical, a platform that delivers trial oversight, analytics, and insights to drive successful study outcomes. With over 50 strategic regulatory consulting engagements, Navitas has delivered 192,000+ submissions to a range of regulatory authorities across the globe.
Backed by insights derived from our proprietary industry networks, and over 300 strategic safety consulting engagements, Navitas supports both in-trial and post-authorization pharmacovigilance to ensure better patient safety. Over the last 17 years, our 10 proprietary industry networks have provided a platform for industry peers to share with and learn from each other. With over 120 members, the ‘nets’ drive the development and adoption of industry best practices and innovations.
Navitas Life Sciences brings together the best minds in the industry to provide life sciences companies with an adaptive, innovative, and reliable partner who delivers better outcomes consistently, across the value chain.

Company’s Keywords:

fullservice clinical trials, incl biosimilars, noninterventional studies, ba, be studies, riskbased monitoring, investigator payments, data management, biostats, data aggregation, regulatory consulting, regulatory submissions & lifecycle management, endtoend labelling, idmp suite, pv consulting, argus, arisg implementation, pv services, clinical consulting, virtual clinical trials, remote clinical trials